At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed May 7, 2026 at 08:00 ET
Solid Biosciences dosed the first participant in its Phase 3 IMPACT DUCHENNE trial for SGT-003, a gene therapy for Duchenne muscular dystrophy, and received a positive EMA opinion on its Pediatric Investigation Plan. The company has dosed 46 participants in the Phase 1/2 INSPIRE DUCHENNE trial with generally well-tolerated safety data as of May 4, 2026. This milestone advances SGT-003 toward potential accelerated approval and global regulatory authorizations.
- First participant dosed in Phase 3 IMPACT DUCHENNE trial (placebo-controlled, randomized, double-blind) for SGT-003 in Duchenne muscular dystrophy.
- Received positive EMA opinion on Pediatric Investigation Plan (PIP) for SGT-003, establishing pediatric development framework in Europe.
- 46 participants dosed with SGT-003 in Phase 1/2 INSPIRE DUCHENNE trial as of May 4, 2026 safety cutoff; generally well tolerated with no drug-induced liver injury, myocarditis, thrombotic microangiopathy, or atypical hemolytic uremic syndrome.
- FDA alignment reached on Phase 3 trial design including primary endpoint of change in time to rise from supine (TTR) velocity at 18 months.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access